Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Covid-19 Vaccine Effectiveness and the Test-Negative Design
Natalie E. Dean, Joseph W. Hogan, Mireille E. Schnitzer
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1431-1433
Open Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 553
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1899-1909
Open Access | Times Cited: 221
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Tal Patalon, Yaki Saciuk, Asaf Peretz, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 135
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
Samantha M. Olson, Margaret M. Newhams, Natasha Halasa, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 8, pp. 713-723
Open Access | Times Cited: 104
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Otávio T. Ranzani, Matt D. T. Hitchings, Rosana Leite de Melo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 87
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
Sivan Gazit, Yaki Saciuk, Galit Perez, et al.
BMJ (2022), pp. e071113-e071113
Open Access | Times Cited: 80
Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors
Margaret K. Doll, Stacy Pettigrew, Julia Ma, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e564-e571
Open Access | Times Cited: 74
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 67
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
Analía Rearte, Juan Manuel Castelli, Ramiro Rearte, et al.
The Lancet (2022) Vol. 399, Iss. 10331, pp. 1254-1264
Open Access | Times Cited: 58
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
Elsie Horne, William Hulme, Ruth H. Keogh, et al.
BMJ (2022), pp. e071249-e071249
Open Access | Times Cited: 54
Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge
Jennifer M. Polinski, Andrew R. Weckstein, Michael Batech, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e222959-e222959
Open Access | Times Cited: 51
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2236670-e2236670
Open Access | Times Cited: 45
Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals
Austin D Vo, Jennifer La, Julie T.-Y. Wu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2240037-e2240037
Open Access | Times Cited: 45
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
Milena Suarez Castillo, Hamid Khaoua, Noémie Courtejoie
Eurosurveillance (2022) Vol. 27, Iss. 16
Open Access | Times Cited: 41
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 41
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
Jessica Widdifield, Jeffrey C. Kwong, Simon Chen, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e430-e440
Open Access | Times Cited: 38
Tracking immune correlates of protection for emerging SARS-CoV-2 variants
Eric J. Nilles, Cecilia Then Paulino, Michael de St. Aubin, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 2, pp. 153-154
Open Access | Times Cited: 25
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design
Houssein H. Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
American Journal of Epidemiology (2023) Vol. 193, Iss. 6, pp. 883-897
Open Access | Times Cited: 25
The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study
Rebecca Kahn, Cara Bess Janusz, Márcia C. Castro, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100474-100474
Open Access | Times Cited: 22
Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study
Sophie Meakin, Justus Nsio, Anton Camacho, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. 1357-1365
Open Access | Times Cited: 8
Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults
Lior Rennert, Zichen Ma, Christopher S. McMahan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design
Houssein H. Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 27
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
William Hulme, Elizabeth Williamson, Elsie Horne, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 5, pp. 685-693
Open Access | Times Cited: 20
Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness
Kendrick Qijun Li, Xu Shi, Miao Wang, et al.
Journal of the American Statistical Association (2023), pp. 1-12
Open Access | Times Cited: 18
BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
Iulia G Ionescu, Danuta M. Skowronski, Chantal Sauvageau, et al.
The Journal of Infectious Diseases (2023) Vol. 227, Iss. 9, pp. 1073-1083
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top